Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medmix AGCHIX:MEDXZ +1.97%66 Return-on-Tangible-Equity is 1.71% as of Jun. 2026, which is 80% below its 10-year median of 8.60. GuruFocus rates CHIX:MEDXZ with a GF Score™ of 66/100 and a GF Value™ of CHF9.05 (Fairly Valued). The stock has 6 warning signs investors should review. Among 2,973 Industrial Products companies, Medmix AG ranks worse than 75.14% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medmix AG's annualized net income for the quarter that ended in Jun. 2026 was CHF1.0 Mil. Medmix AG's average shareholder tangible equity for the quarter that ended in Jun. 2026 was CHF58.5 Mil. Therefore, Medmix AG's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 1.71%.
The historical rank and industry rank for Medmix AG's Return-on-Tangible-Equity or its related term are showing as below:
CHIX:MEDXz'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -12.65 Med: 8.6 Max: 178.5
Current: 0.18
During the past 8 years, Medmix AG's highest Return-on-Tangible-Equity was 178.50%. The lowest was -12.65%. And the median was 8.60%.
CHIX:MEDXz's Return-on-Tangible-Equity is ranked worse than 75.14% of 2973
companies
in the Industrial Products industry
Industry Median: 6.76
vs CHIX:MEDXz: 0.18
Medmix AG (CHIX:MEDXz) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medmix AG Return-on-Tangible-Equity Related Terms
Medmix AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medmix AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:MEDXZ vs GEV, ETN, PH: Return-on-Tangible-Equity Comparison
For the Specialty Industrial Machinery subindustry, Medmix AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG Return-on-Tangible-Equity vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medmix AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 1.71% mean?
Medmix AG (CHIX:MEDXZ) has a Return-on-Tangible-Equity of 1.71% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medmix AG and its competitors. This is 80% below median its historical median of 8.60. According to the industry distribution chart, Medmix AG ranks #2234 out of 2973 companies in the Industrial Products industry, placing it in the top 75.1%.
Is Medmix AG's Return-on-Tangible-Equity too high?
Medmix AG's current Return-on-Tangible-Equity of 1.71% is 80% below median its 10-year median of 8.60. The Industrial Products industry median Return-on-Tangible-Equity is 6.76. Medmix AG's value of 1.71% is 74.7% below this industry median. Based on the distribution chart, Medmix AG ranks #2234 out of 2973 companies in the Industrial Products industry, which is in the bottom quartile relative to peers. Overall, Medmix AG has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's Return-on-Tangible-Equity compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Medmix AG ranks #2234 out of 2973 companies for Return-on-Tangible-Equity. This places Medmix AG in the lower half of its industry. The industry median Return-on-Tangible-Equity is 6.76. Medmix AG's value of 1.71% is 74.7% below this benchmark. While the company's 10-year median is 8.60 vs. the industry median of 6.76, Medmix AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Industrial Products company?
The median Return-on-Tangible-Equity among Industrial Products companies is 6.76, based on 2,973 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current Return-on-Tangible-Equity of 1.71% is 74.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medmix AG and its competitors. For the Industrial Products industry, the median Return-on-Tangible-Equity is 6.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current Return-on-Tangible-Equity is 1.71%, which is 80% below median its own 10-year median of 8.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Based on GuruFocus' analysis, Medmix AG (CHIX:MEDXZ) is currently considered Fairly Valued. The stock's GF Value™ is CHF9.05, compared to a current price of CHF8.54 — trading 5.7% below its estimated fair value. The current Return-on-Tangible-Equity is 1.71%, which is 80% below median its 10-year median of 8.60 and 74.7% below the Industrial Products industry median of 6.76. Medmix AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medmix AG (CHIX:MEDXZ), the current Return-on-Tangible-Equity is 1.71% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (CHIX:MEDXZ) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued.
The current stock price of CHF8.54 is trading 5.7% below its estimated GF Value™ of CHF9.05.
GuruFocus considers Medmix AG to be Fairly Valued.
Key valuation signals for CHIX:MEDXZ:
Return-on-Tangible-Equity: 1.71% (80% below median its 10-year median of 8.60)
GF Value™: CHF9.05 vs. price of CHF8.54 (5.7% below fair value)
Industry Position: 74.7% below the Industrial Products median (#2234 of 2973)
No single metric tells the full story. See the CHIX:MEDXZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
66GF Score
Get the complete analysis for CHIX:MEDXZ
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:MEDXZ has been successfully added to your 
